Reclast (Zoledronic Acid) Cost in Mississippi: 2026 Pricing, Insurance, and Savings Guide

What Reclast (Zoledronic Acid) Actually Costs in Mississippi in 2026

The sticker price and the price patients pay are two different numbers. Novartis lists Reclast at roughly $1,500 per infusion, but the average out-of-pocket cost across Mississippi retail pharmacies and infusion centers sits closer to $600 when paying cash in 2026. That gap exists because generic zoledronic acid entered the market after Reclast's patent expiration, and competition has compressed actual transaction prices well below the branded list.

Zoledronic acid is a bisphosphonate administered as a single 5 mg intravenous infusion once per year for treatment of postmenopausal osteoporosis. In the HORIZON Key Fracture Trial (HORIZON-PFT, N=7,765), annual zoledronic acid infusion reduced morphometric vertebral fractures by 70% and hip fractures by 41% over three years compared with placebo [1]. That once-yearly dosing schedule means the total annual drug cost is a single charge, unlike oral bisphosphonates requiring weekly or monthly fills.

The $600 average cash price in Mississippi includes only the drug itself. Patients also face facility or infusion-center fees, which vary from $150 to $400 depending on whether the infusion occurs in a hospital outpatient department, a freestanding infusion suite, or a physician's office. A physician-office infusion in Mississippi typically runs the lowest total cost. Patients should request an itemized estimate before scheduling.

Mississippi Medicaid Does Not Cover Reclast for Osteoporosis

Mississippi's Medicaid program does not include Reclast or generic zoledronic acid on its preferred drug list for the osteoporosis indication as of 2026. This is a gap that affects a significant portion of the state's population. According to U.S. Census Bureau data analyzed by the Kaiser Family Foundation, Mississippi has one of the highest Medicaid enrollment rates in the country, yet the program steers osteoporosis patients toward oral bisphosphonates such as alendronate, which the FDA approved as a first-line therapy and which costs under $15 per month in generic form.

Patients on Mississippi Medicaid who cannot tolerate oral bisphosphonates (due to esophageal disorders, inability to remain upright for 30 minutes, or documented gastrointestinal adverse events) may pursue a prior authorization exception. The prescribing physician must document the clinical rationale, including the specific oral agent tried, the duration of therapy, and the adverse outcome. Approval is not guaranteed. The Mississippi Division of Medicaid reviews these requests on a case-by-case basis.

For Medicaid patients denied coverage, two fallback options exist: the Novartis Patient Assistance Program (PAP) for qualifying income thresholds, or referral to a Federally Qualified Health Center (FQHC) that participates in the 340B Drug Pricing Program, where zoledronic acid may be available at a steep institutional discount.

Medicare Part B Coverage for Zoledronic Acid Infusions

Because zoledronic acid is a physician-administered injectable, it falls under Medicare Part B's medical benefit rather than Part D's pharmacy benefit. This distinction matters. Under Part B, Medicare typically covers 80% of the allowed amount after the annual deductible, leaving the patient responsible for 20% coinsurance.

For a $600 drug cost, the patient's coinsurance lands around $120 per infusion, plus a share of the administration fee. Patients with a Medigap (Medicare Supplement) plan may have that 20% covered entirely. Medicare Advantage plans in Mississippi vary by carrier, but most include zoledronic acid on their medical benefit formulary because the Endocrine Society's 2020 clinical practice guideline recommends IV zoledronic acid as a first-line option for patients at high fracture risk.

Dr. Ethel Siris, a professor of medicine at Columbia University Medical Center who has published extensively on osteoporosis epidemiology, has stated: "Zoledronic acid's once-yearly dosing eliminates the adherence problem that plagues oral bisphosphonate therapy, where more than half of patients discontinue within the first year." That adherence advantage may justify the higher per-dose cost compared with generic alendronate.

Commercial Insurance Coverage Across Mississippi

Most major commercial insurers operating in Mississippi (Blue Cross Blue Shield of Mississippi, Humana, Cigna, UnitedHealthcare, and Aetna) cover zoledronic acid infusion under the medical benefit with prior authorization. The prior authorization typically requires documentation of a dual-energy X-ray absorptiometry (DXA) scan showing a T-score of -2.5 or below, or a T-score between -1.0 and -2.5 with a FRAX 10-year major osteoporotic fracture probability exceeding 20%.

Step therapy is common. Several Mississippi plans require a 90-day trial (or documented intolerance) of an oral bisphosphonate before approving zoledronic acid. Patients who have already tried and failed alendronate or risedronate should bring pharmacy records to the prescriber's office so the prior authorization submission includes verifiable fill dates.

Out-of-pocket costs for commercially insured patients range from $0 (with a manufacturer co-pay card) to $300 per infusion, depending on plan design. Self-funded employer plans, which cover a large share of Mississippi's privately insured workforce, set their own formulary rules and may be more or less restrictive than state-regulated plans.

The Novartis Savings Card and Generic Discount Programs

Novartis offers a co-pay assistance card for commercially insured patients receiving branded Reclast. The card can reduce the patient's out-of-pocket share to as little as $0 for eligible infusions, with an annual cap that Novartis adjusts periodically. The card does not apply to patients covered by Medicare, Medicaid, Tricare, or other government-funded programs. Federal anti-kickback statutes prohibit manufacturer co-pay cards for government beneficiaries.

For uninsured or underinsured patients, the Novartis Patient Assistance Foundation provides free branded Reclast to individuals with household incomes at or below 500% of the federal poverty level. A Mississippi household of two earning under approximately $51,150 in 2026 may qualify. Application requires prescriber certification and proof of income.

Generic zoledronic acid (manufactured by Mylan, Teva, Hospira, and others) carries no branded savings card, but the generic price itself is the discount. Cash-pay pricing for generic zoledronic acid at Mississippi pharmacies averages $400 to $600, and GoodRx-type coupon aggregators may reduce that range by another 10% to 20%. Patients should compare prices between independent infusion pharmacies and large hospital systems, as hospital outpatient department markups can be 2 to 3 times higher than independent infusion center pricing for the identical drug.

Compounded Zoledronic Acid via 503A Pharmacies in Mississippi

Mississippi permits licensed 503A compounding pharmacies to prepare zoledronic acid formulations when a patient-specific prescription exists. Under the FDA's Section 503A of the Food, Drug, and Cosmetic Act, a 503A pharmacy may compound a drug for an individual patient based on a valid prescription, provided the pharmacy does not compound copies of commercially available products in essentially the same formulation.

This creates a regulatory nuance. Because FDA-approved zoledronic acid injection (5 mg/100 mL) is commercially available, a 503A pharmacy compounding an identical concentration could face scrutiny. In practice, compounding pharmacies may prepare zoledronic acid in a different concentration, volume, or with a different inactive ingredient profile to stay within the 503A exemption. Patients considering this route should confirm that their prescriber specifically writes for the compounded formulation and that the pharmacy holds a current Mississippi Board of Pharmacy compounding license.

Cost through 503A compounding varies. Some Mississippi 503A pharmacies advertise significantly lower pricing than commercial generics, though patients should weigh the lower price against the absence of FDA batch-level manufacturing oversight that applies to approved generic products. The American Society of Health-System Pharmacists (ASHP) has published guidelines emphasizing the importance of verifying compounding pharmacy accreditation.

Telehealth Prescribing of Zoledronic Acid in Mississippi

Mississippi law permits telehealth prescribing of zoledronic acid. A physician can evaluate a patient via synchronous audio-video visit, review DXA results and lab work electronically, and transmit the prescription to an infusion pharmacy or facility. The infusion itself must still occur in person at a licensed facility, since zoledronic acid requires intravenous administration over at least 15 minutes with post-infusion monitoring.

The Mississippi State Board of Medical Licensure requires the prescribing physician to hold a valid Mississippi medical license or participate in an interstate compact. Patients in rural Mississippi counties without local endocrinologists or rheumatologists can use telehealth to access specialists in Jackson, Hattiesburg, or other metro areas, then receive the infusion at a local facility.

Pre-infusion labs (serum calcium, creatinine, and 25-hydroxyvitamin D) can be drawn at any Mississippi laboratory location before the telehealth consultation. The prescriber reviews results during the visit and, if appropriate, sends the zoledronic acid order to the patient's preferred infusion site. This workflow eliminates the need for two in-person visits.

How to Find the Lowest Zoledronic Acid Price in Mississippi

Price transparency in Mississippi's infusion market remains limited, so patients need to take an active role. Three concrete steps reduce cost:

First, call at least three infusion sites and request the "self-pay" or "uninsured" rate for a zoledronic acid infusion including drug and administration. Hospital outpatient departments in Mississippi charge, on average, 40% to 60% more than physician offices for the same infusion, according to CMS Hospital Outpatient Prospective Payment System data.

Second, ask the prescriber to write for generic zoledronic acid rather than branded Reclast. The clinical evidence supporting generic zoledronic acid is identical because the FDA requires bioequivalence testing for all approved generics.

Third, check eligibility for the 340B program. Mississippi has 52 FQHC sites and several 340B-eligible hospital systems. Patients treated at these facilities may access zoledronic acid at the 340B ceiling price, which can be 25% to 50% below the average wholesale price. Eligibility is tied to the treatment site, not the patient's insurance status.

The 2019 National Osteoporosis Foundation survey (now the Bone Health and Osteoporosis Foundation) found that 28% of patients prescribed injectable osteoporosis therapy never filled the prescription due to cost concerns. Dr. Andrea Singer, chief medical officer of the Bone Health and Osteoporosis Foundation, noted: "Cost should never be the reason a patient with osteoporosis goes untreated, given that hip fractures carry a 20% one-year mortality rate in older adults."

Clinical Context: Why Zoledronic Acid Over Oral Options

Zoledronic acid's cost discussion is incomplete without clinical context. In the HORIZON-PFT trial, 5 mg IV zoledronic acid once yearly reduced vertebral fractures by 70% (3.3% vs. 10.9%, P<0.001), hip fractures by 41% (1.4% vs. 2.5%, P=0.002), and nonvertebral fractures by 25% (8.0% vs. 10.7%, P=0.001) over three years [1]. The HORIZON Recurrent Fracture Trial (N=2,127) showed a 35% reduction in new clinical fractures and a 28% reduction in all-cause mortality in patients who received zoledronic acid after hip fracture repair [2].

Oral alendronate, while effective, suffers from adherence decay. A 2012 meta-analysis in Osteoporosis International reported that only 40% to 50% of patients remained adherent to oral bisphosphonates at 12 months. Zoledronic acid's once-yearly dosing bypasses this problem entirely. For patients in Mississippi weighing a $15/month alendronate prescription against a single $600 annual infusion, the total annual cost difference is modest ($180 vs. $600), but the fracture-prevention benefit may favor the IV route if adherence to daily or weekly oral dosing is uncertain.

Common adverse effects of zoledronic acid include an acute-phase reaction (fever, myalgia, headache) in approximately 30% of patients after the first infusion, declining to under 7% with subsequent infusions [1]. The infusion is contraindicated in patients with creatinine clearance below 35 mL/min and in those with hypocalcemia, which must be corrected before administration.